Abstract:
Disclosed herein is a novel class of aminophenyl compounds having the structure (I) wherein R 1 is cyano or nitro and ring A is a bi- or tricyclic bridged heterocycle and to their use as modulators of androgen receptor for the treatment or prevention of conditions relating thereto.
Abstract:
The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
Abstract:
Provided herein are compounds that selected from Formula I, Formula Ia, Formula II, Formula IIa, Formula IIb, Formula III, Formula IV, Formula V and Formula VI: bind to androgen receptors and modulate the activity and/or the amount of androgen receptors and to methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.
Abstract:
The present invention is directed to a new class of benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.
Abstract:
Disclosed herein is a novel class of aminophenyl compounds having the structure (I) wherein R 1 is cyano or nitro and ring A is a bi- or tricyclic bridged heterocycle and to their use as modulators of androgen receptor for the treatment or prevention of conditions relating thereto.
Abstract:
The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
Abstract:
The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.
Abstract:
The present invention relates to a method of treating hypogonadal males as well as to a method of treating or preventing: wasting syndrome, anti-retroviral drug induced lipodystrophia, lack of well-being or fatigue in HIV infected individuals; catabolic state; leydig cell dysfunction and germinal epithelial damage following cytotoxic chemotherapy; fatigue, reduction in hemoglobine or neutrophil count during or subsequent to cytotoxic chemotherapy or radiotherapy; benign gynaecological disorders; or delayed puberty; and in a method of weight maintenance. More specifically the invention is concerned with a method of treatment that comprises pulmonary administration of an effective amount of 6α-alkyl and/or 7α-alkyl-androgen. Another aspect of the invention is concerned with a pulmonary drug delivery composition based on biodegradable microparticles containing the 6α-alkyl and/or 7α-alkyl-androgen. Furthermore, the invention relates to an aerosol drug delivery system comprising an aerosol delivery device and a liquid pharmaceutical composition containing said 6α-alkyl and/or 7α-alkyl-androgen.
Abstract:
This invention relates to non-steroidal tricyclic compounds that are modulators of androgen receptors and to methods for making and using such compounds.